No Data
Defence Receives No Objection Letter From Health Canada for Phase I Trial of Its ACCUM-002 (AccuTOX) as an Anti-Cancer Molecule in Patients With Melanoma
Defence's AccuTOX Boosts and Synergizes With Immune Checkpoint Inhibitors
Defence's ARM-X Anti-Cancer Vaccine Inhibits Growth of Pre-Established Ovarian Cancer Resulting in Complete Responses in Treated Animals
Defence's Chief Scientific Officer Dr. Moutih Rafei Discusses the Accum Platform for Cancer Treatments on Money Talk Radio With Ellis Martin
Defence to Participate in 2024 Society of Nuclear Medicine and Molecular Imaging Annual Meeting in Toronto on June 11, 2024
Defence's AccuTOX Published in the Prestigious Journal of Translational Medicine Its Peer Study With Preclinical Data on AccuTOX as an Anti-Cancer Molecule
